Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Sees Large Decline in Short Interest

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 158,200 shares, a decline of 23.8% from the November 30th total of 207,700 shares. Based on an average daily trading volume, of 22,500 shares, the days-to-cover ratio is currently 7.0 days.

Medexus Pharmaceuticals Trading Up 5.6 %

Medexus Pharmaceuticals stock opened at $2.27 on Friday. Medexus Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $2.35. The firm’s 50-day simple moving average is $1.84 and its 200 day simple moving average is $1.74.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.